SUNPHARMA Ltd.

446.3INR + 1.70 (+ 0.38%) VOLUME : 3412716
    Average Volume
  • 5-Day 4,478,270.80
  • 20-Day 5,147,267.60
  • 3-Months 5,922,355.82

MARKET CLOSED

Price Table

Date Open High GREEN: if High is higher than last 2 days high
RED: if high is lower than last 2 days high
Low GREEN:if Low is higher than last 2 days low
RED: if low is lower than last 2 days low
LTP Close GREEN:if Day's Closing is near the Day's High
RED: if low is lower than last 2 days low
Volume Delivery % 20 Day SMA GREEN: if Day's Closing is above 20-Day SMA
RED: if Day's Closing is below 20-Day SMA
50 Day SMA GREEN: if Day's Closing is above 50-Day SMA
RED: if Day's Closing is below 50-Day SMA
100 Day SMA GREEN: if Day's Closing is above 100-Day SMA
RED: if Day's Closing is below 100-Day SMA
200 Day SMA GREEN: if Day's Closing is above 200-Day SMA
RED: if Day's Closing is below 200-Day SMA
22-Jan-20 448.40 453.85 445.35 446.30 446.30 3,412,716 - - - - -
13-Jan-20 447.00 453.65 442.55 444.80 444.60 4,823,348 26% 435.26 435.52 424.02 425.46
10-Jan-20 440.10 449.00 440.00 444.75 443.60 4,334,013 20% 435.00 435.29 423.75 425.57
09-Jan-20 442.70 444.85 439.00 439.95 439.85 3,934,566 47% 434.52 435.01 423.71 425.67
08-Jan-20 442.95 446.50 439.00 439.10 440.10 3,881,918 41% 434.02 434.65 423.53 425.80
07-Jan-20 441.40 448.00 437.55 447.05 446.40 4,504,083 32% 433.40 434.21 423.39 425.89
06-Jan-20 440.90 444.70 435.10 439.00 439.95 4,794,923 24% 432.43 433.63 423.14 426.00
03-Jan-20 434.65 450.40 433.05 443.15 444.60 9,457,180 26% 431.86 432.95 422.92 426.10

Performance

Key Data

Day High Low Range

Time Lowest Highest
10 AM 448.40 453.85
11 AM 448.40 453.85
12 PM 447.75 453.85
1 PM 447.25 453.85
2 PM 446.60 453.85

Company Profile - SUNPHARMA Ltd.

SUNPHARMA

Sun Pharmaceutical Industries began with just five products for treating psychiatry ailments in the year 1983. Its sales were initially limited to only two states such as West Bengal and Bihar. Soon, its sales were rolled out nationally in the year 1985. Also, the products being used in cardiology were introduced in 1987, and Monotrate, which is one of the first products introduced at that time, it became one of our largest selling products. Also, several other vital products in Cardiology were added; and several of these were being introduced in India. It was also listed on the main stock exchanges in India in 1994. It is an international specialty pharma company, along with a presence in 30+ markets. It also makes several active pharmaceutical ingredients. And in branded markets, its products are recommended in chronic therapy areas such as psychiatry, cardiology, neurology, diabetology, gastroenterology, and respiratory. Also, knowing the fact ... that research is a critical growth driver, they soon established their research center SPARC in 1993, and it created a base of robust product and process development skills. In India, it has reached leadership in almost each of the therapy areas where we operate, and it’s also rated among the leading companies by key customers. So, growing market share and retaining this customer focus persists to be a high priority area for the company. The other API plant, its Ahmednagar plant, was being acquired from the multinational Knoll Pharmaceuticals in 1996, and also upgraded for approvals from regulated markets, along with substantial capacity besides over the years. It was the first of many sensibly priced acquisitions, each of that would bring essential parts to the long-term strategy. Also, with world-class technology and a team of robust professionals, it built sites and systems that could meet the most stringent international manufacturing standards. Also, the expert quality teams ensure that both systems and processes remain in compliance, along with the latest standards. Also, several plants hold approvals from both the USFDA and the UK MHRA. Both APIs and Dosage forms were made in 19 sites across India, Hungary, the US, and Bangladesh.
  • Formulation:It is a market leader in specialty therapy areas, along with high-quality brands trusted for the chronic disease. Its comprehensive product basket and products, along with technology-based differentiation, are the highlights. It makes specialty formulations across a spectrum of dosage forms such as oral, injectable, and delivery system based.
  • API:Its API (or Active Pharmaceutical Ingredients) program started in 1995 with a simple objective- of facilitating the manufacture of complicated formulations, and for that sourcing the API will restrict entry. It also makes specialty APIs that include steroids, peptides, hormones, and anticancer at an internationally approved world-class site. It also has over 1600 registrations in 30 countries, and more than 1000 registrations filed and pending approval. In such countries, it uses the same approach to specialty brand building as well as customer focus that has worked for it in India.

The Manufacturing of product in the following therapy areas:

  • CNS disorders
  • Cardiology
  • Diabetes and Metabolic disorders
  • Gastroenterology
  • Ophthalmology
  • Oncology
  • Pain
  • Allergy, Asthma, and Inflammation
  • Gynecological

Some Other group companies:

  • Caraco Pharmaceutical Laboratories:It is based in Detroit, Michigan. Caraco develops, and manufactures, and markets and distributes generic and private-label pharmaceuticals and markets them across the United States.
  • Sun Pharmaceutical Industries Inc. (or SPI):It is a Michigan Corporation and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd, India. Its plant is spread over 35,000 sq ft, in Bryan, Ohio, and manufactures creams, liquids, and ointments. It was being purchased from Valeant Pharma.
  • Sun Pharmaceutical (Bangladesh):It is a private limited company and was incorporated in March 2001 under the Companies Act 1994. It was formed joined with Sun Pharma, City Overseas Ltd, which is a company incorporated in Bangladesh and Sun Pharma Global Inc, which is a company that was incorporated under the laws of the British Virgin Islands. It began its commercial operations on October 2004. It owns and operates a pharmaceutical factory and also makes pharmaceutical products that are being sold in the local market.
  • Alkaloids Chemical Company Exclusive Group Ltd.:ICN Hungary, acquired from Valeant Pharmaceuticals in 2005, it is one of the few units globally and authorized to make controlled substances. Also, ICN Hungary is renamed as Alkaloids Chemical Company.

Some of the Milestones:

  • 2008:In November 2008, it along with its subsidiaries, acquired 100% ownership of the Chattem Chemicals, Inc., which is a narcotic raw material importer and manufacturer of the controlled substances with an approved facility in Tennessee. It will offer vertical integration for all of its controlled substance dosage form businesses in the US.
  • 2011:Dilip Shanghvi, CMD, also received the E&Y Entrepreneur of the Year Award in 2010. (ORG – Operations Research Group Audit of the Retail Chemist Sales, soon after renamed the IMS - ORG Retail Store Audit. Also, both ORG and IMS are the trademarks of their registered owners).
  • 2014:On April 6, 2014, the Sun Pharmaceutical Industries and Ranbaxy Laboratories declared that they have entered into definitive agreements according to which Sun Pharma would acquire 100% of Ranbaxy in an all-stock transaction.

Some of the Achievements:

  • It was also selected as the best company by Express Pharma Pulse, for overall performance in 2002.
  • The four manufacturing sites won the prestigious IDMA awards.
  • The Forbes Global ranked Sun Pharma in the list of the best small 200 companies for 2003.
  • The Forbes Global ranked Sun Pharma in the list of most valuable companies for 2004.